CytoDyn Inc. (CYDY) News
Follow CytoDyn Inc. (CYDY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
CytoDyn Reports Quarterly Net Loss
CytoDyn reported a net loss for the quarter ended Aug. 31, 2026, compared with a larger loss in the year-ago quarter. Diluted loss per share was also reported as a loss, versus a loss per share of zero in 3Q 2025. The co
EQUITY | Oct 14, 2026, 12:41 PM UTC
L
CytoDyn closes $16.5 million financing to fund leronlimab development
CytoDyn says it has closed a $16.5 million financing to fund continued development of leronlimab, its humanized monoclonal antibody targeting the CCR5 receptor.
EQUITY | Sep 01, 2026, 12:37 PM UTC